

PATENT

3158/02/US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

PEREZ ET AL

GROUP ART UNIT: TBD

SERIAL NUMBER: TBD

EXAMINER: TBD

FILED: TBD

DATE: 8 JAN 04

TITLE: COMBINATION THERAPY OF ANGIOTENSIN CONVERTING ENZYME
INHIBITOR AND ALDOSTERONE ANTAGONIST FOR REDUCING MORBIDITY AND
MORTALITY FROM CARDIOVASCULAR DISEASE

I hereby certify that this correspondence is being
deposited with the United States Postal Service as
EXPRESS MAIL #EV418193642US in an envelope addressed to:
Commissioner for Patents,
United States Patent and Trademark Office,
Alexandria, VA 22313-1450
on 8 JAN 04
JOSEPH R. SCHUH
Registration No. 48,180

Joseph R. Schuh

Date:

8 Jan 04

PRELIMINARY AMENDMENT

TO THE COMMISSIONER OF PATENTS AND TRADEMARKS
Alexandria, VA 22313-1450
SIR:

Please amend the subject patent application as follows:

IN THE SPECIFICATION

On page 1, delete Lines 5-13 and insert the following:


-- CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of prior U.S.
Application Serial No. 10/077,134 filed February 15, 2002,
soon to issue as a U.S. Patent, which is a continuation of
U.S. Application Serial No. 09/434,685 filed on November 5,

1999, which issued on June 25, 2002 as U.S. Patent No. 6,410,524, which application claims priority from U.S. provisional patent application Ser. No. 60/107,398 filed on November 6, 1998; U.S. provisional patent application Ser. No. 60/122,977 filed on March 5, 1998; and U.S. provisional patent application Ser. No. 60/122,978 filed on March 5, 1998. Each of these priority applications is specifically incorporated herein by reference. --

The Commissioner is hereby authorized to charge Deposit Account No. 19-1025 any amounts to cover fees for filing this Preliminary Amendment, or any fees for extensions of time, together with any fees under 37 CFR 1.16 and 1.17 that may be required during the entire pendency of this application.

Respectfully submitted,



Joseph R. Schuh
Agent for Applicants
Registration No. 48,180

PHARMACIA CORPORATION
of Pfizer Inc.
Corporate Patent Department
P. O. Box 1027
Chesterfield, MO 63006